Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastases

BMC Cancer

Ahsan Siraj⁸  Virginie Desestret³  Martine Antoine⁴  Gaëlle Fromont⁶  Michel Huerre⁵  Marc Sanson²  Philippe Camparo⁷  Christophe Pichon⁸  François Planeix⁸  Julie Gonin⁴  Aurelian Radu¹  Nicolae Ghinea⁸ 

[1] Icahn School of Medicine at Mount Sinai, New York, NY, USA

[2] Inserm-UMR975; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2, Paris, France

[3] AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratoire de Neuropathologie, R. Escourolle, Paris, France

[4] Département de Pathologie, Hôpital Tenon, Paris, France

[5] Département de Pathologie, Paris, France; Institut Pasteur, Department Infection et Epidémiologie, Hôpital Curie, Paris, France

[6] Département de Pathologie, CHU de Poitiers, 86000, Poitiers, France

[7] Centre de Pathologie Amiens, Amiens, France

[8] Inserm Equipe Angiogenèse Tumorale, Institut Curie, Centre de Recherche, Département Recherche Translationnelle, 26 rue d’Ulm, 75005, Paris, France

关键词: Tumor blood vessels;    Metastasis;    Follicle-stimulating hormone receptor;    Leiomyosarcoma;    Endothelial cells;    Prostate cancer;    Lung cancer;    Kidney cancer;    Colon cancer;    Breast cancer;   

Others  :  1079745
DOI  :  10.1186/1471-2407-13-246

 received in 2012-12-17, accepted in 2013-05-16,  发布年份 2013

【 摘 要 】

Background

The Follicle Stimulating Hormone receptor (FSHR) is expressed by the vascular endothelium in a wide range of human tumors. It was not determined however if FSHR is present in metastases which are responsible for the terminal illness.

Methods

We used immunohistochemistry based on a highly FSHR-specific monoclonal antibody to detect FSHR in cancer metastases from 6 major tumor types (lung, breast, prostate, colon, kidney, and leiomyosarcoma ) to 6 frequent locations (bone, liver, lymph node, brain, lung, and pleura) of 209 patients.

Results

In 166 patients examined (79%), FSHR was expressed by blood vessels associated with metastatic tissue. FSHR-positive vessels were present in the interior of the tumors and some few millimeters outside, in the normally appearing tissue. In the interior of the metastases, the density of the FSHR-positive vessels was constant up to 7 mm, the maximum depth available in the analyzed sections. No significant differences were noticed between the density of FSHR-positive vessels inside vs. outside tumors for metastases from lung, breast, colon, and kidney cancers. In contrast, for prostate cancer metastases, the density of FSHR-positive vessels was about 3-fold higher at the exterior of the tumor compared to the interior. Among brain metastases, the density of FSHR-positive vessels was highest in lung and kidney cancer, and lowest in prostate and colon cancer. In metastases of breast cancer to the lung pleura, the percentage of blood vessels expressing FSHR was positively correlated with the progesterone receptor level, but not with either HER-2 or estrogen receptors. In normal tissues corresponding to the host organs for the analyzed metastases, obtained from patients not known to have cancer, FSHR staining was absent, with the exception of approx. 1% of the vessels in non tumoral temporal lobe epilepsy samples.

Conclusion

FSHR is expressed by the endothelium of blood vessels in the majority of metastatic tumors.

【 授权许可】

   
2013 Siraj et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Sprengel R, Braun T, Nikolics K, Segaloff DL, Seeburg PH: The testicular receptor for follicle-stimulating hormone: structure and functional expression of cloned cDNA. Mol Endocrinol 1990, 4:525-530.
• [2]Simoni M, Gromoll J, Nieschlag E: The follicle stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology. Endocr Rev 1997, 18:739-773.
• [3]Vannier B, Loosfelt H, Meduri G, Pichon C, Milgrom E: Anti-human FSH receptor monoclonal antibodies: immunochemical and immunocytochemical characterization of the receptor. Biochemistry 1996, 35:1358-1366.
• [4]Vu Hai MT, Lescop P, Loosfelt H, Ghinea N: Receptor-mediated transcytosis of follicle stimulating hormone through the rat testicular microvasculature. Biol Cell 2004, 96:133-144.
• [5]Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A, Fromont G, Vu Hai MT, Ghinea N: Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med 2010, 363:1621-1630.
• [6]Siraj MA, Pichon C, Radu A, Ghinea N: Endothelial FSH receptor in primary kidney cancer correlates with subsequent response to sunitinib. J Cell Mol Med 2012, 16:2010-2016.
• [7]Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, van't Veer LJ: Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci USA 2003, 100:15901-15905.
• [8]Weigelt B, Peterse JL, van’t Veer LJ: Breast cancer metastasis: markers and models. Nature Rev Cancer 2005, 5:591-602.
• [9]Takes RP, Baatenburg de Jong RJ, Wijffels K, Schuuring E, Litvinov SV, Hermans J, van Krieken JH: Expression of genetic markers in lymph node metastases compared with their primary tumours in head and neck cancer. J Pathol 2001, 194:298-302.
• [10]Ljuslinder I, Malmer B, Isaksson-Mettävainio M, Oberg A, Henriksson R, Stenling R, Palmqvist R: ErbB 1-4 expression alterations in primary colorectal cancers and their corresponding metastases. Anticancer Res 2009, 29:1489-1494.
• [11]Stoecklein NH, Klein CA: Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int J Cancer 2010, 126:589-598.
• [12]Aird WC: Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 2007, 100:158-173.
• [13]Aird WC: Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circ Res 2007, 100:174-190.
• [14]Boegehold MA: Heterogeneity of endothelial function within the circulation. Curr Opin Nephrol Hypertens 1998, 7:71-78.
• [15]Ribatti D, Nico B, Vacca A, Roncali L, Dammacco F: Endothelial cell heterogeneity and organ specificity. J Hematother Stem Cell Res 2002, 11:81-90.
• [16]Thorin E, Shreeve SM: Heterogeneity of vascular endothelial cells in normal and disease states. Pharmacol Ther 1998, 78:155-166.
• [17]Ghinea N, Milgrom E: Transport of protein hormones through the vascular endothelium. J Endocrinol 1995, 145:1-9.
• [18]Nakamoto RH, Uetake H, Iida S, Kolev YV, Soumaoro LT, Takagi Y, Yasuno M, Sugihara K: Correlations between cyclooxygenase-2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer. Jpn J Clin Oncol 2007, 37:679-685.
• [19]Rajaganeshan R, Prasad R, Guillou PJ, Chalmers CR, Scott N, Sarkar R, Poston G, Jayne DG: The influence of invasive growth pattern and microvessel density on prognosis in colorectal cancer and colorectal liver metastases. Br J Cancer 2007, 96:1112-1117.
• [20]Mooteri S, Rubin D, Leurgans S, Jakate S, Drab E, Saclarides T: Tumor angiogenesis in primary and metastatic colorectal cancers. Dis Colon Rectum 1996, 39:1073-1080.
• [21]Prall F, Gringmuth U, Nizze H, Barten M: Microvessel densities and microvascular architecture in colorectal carcinomas and their liver metastases: significant correlation of high microvessel densities with better survival. Histopathology 2003, 42:482-491.
• [22]Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for highthroughput molecular profiling of tumor specimens. Nat Med 1998, 4:844-847.
• [23]Reyal F, Rouzier R, Depont-Hazelzet B, Bollet MA, Pierga JY, Alran S, Salmon RJ, Fourchotte V, Vincent-Salomon A, Sastre-Garau X, Antoine M, Uzan S, Sigal-Zafrani B, De Rycke Y: The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma. PLoS One 2011, 6(5):e20297.
• [24]Tokai H, Kawashita Y, Eguchi S, Kamohara Y, Takatsuki M, Okudaira S, Tajima Y, Hayashi T, Kanematsu T: A case of mucin producing liver metastases with intrabiliary extension. World J Gastroenterol 2006, 12:4918-4921.
• [25]Uehara K, Hasegawa H, Ogiso S, Sakomoto E, Igami S, Mori T: Intrabiliary polypoid growth of liver metastasis from colonic adenocarcinoma with minimal invasion of the liver parenchyma. J Gastroenterol 2004, 39:72-75.
• [26]Meehan B, Appu S, St Croix B, Rak-Poznanska K, Klotz L, Rak J: Age-related properties of the tumour vasculature in renal cell carcinoma. BJU Int 2011, 107:416-424.
• [27]Stollman TH, Ruers TJ, Oyen WJ, Boerman OC: New targeted probes for radioimaging of angiogenesis. Methods 2009, 48:188-192.
• [28]Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA: Tumor regression by targeted gene delivery to the neovasculature. Science 2002, 296:2404-2407.
• [29]Ghinea N: A novel role for FSH receptor as a tumor endothelial cell marker. Acta Endocrinologica (Buc) 2010, 6:507-512.